share_log

KalVista Shares New Data on HAE Pill, Highlighting Early Treatment Results at ACAAI Conference

Benzinga ·  Oct 28, 2024 18:33

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced the presentation of new sebetralstat data at the American College of Allergy Asthma and Immunology (ACAAI) taking place in Boston, MA from October 24 - 28, 2024.

Tim Craig, DO, Professor, Departments of Medicine and Pediatrics, Division of Pulmonary, Allergy and Critical Care Medicine, Penn State Health, and KONFIDENT investigator, presented data on theCorrelation of Time to Treatment with Attack Duration in the Sebetralstat KONFIDENT Phase 3 Trialthat showed complete attack resolution was achieved faster in attacks that were treated earlier (1st quartile) compared with those treated later (4th quartile).

"This is the first time in a Phase...

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment